[go: up one dir, main page]

MA28689B1 - Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese - Google Patents

Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese

Info

Publication number
MA28689B1
MA28689B1 MA29573A MA29573A MA28689B1 MA 28689 B1 MA28689 B1 MA 28689B1 MA 29573 A MA29573 A MA 29573A MA 29573 A MA29573 A MA 29573A MA 28689 B1 MA28689 B1 MA 28689B1
Authority
MA
Morocco
Prior art keywords
pyrrozolotriazine
angiogenesis
treatment
diseases associated
hyperproliferative disorders
Prior art date
Application number
MA29573A
Other languages
English (en)
Inventor
Catherine Brennan
Karl Miranda
Brent Chandler
Barton Phillips
Jianmei Fan
Michael Brands
Andrea Mcclure
Benjamin Jones
Wenlang Fu
Donald Bierer
Steven Magnuson
Harold C E Kluender
Julie A Dixon
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28689(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA28689B1 publication Critical patent/MA28689B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA29573A 2004-06-03 2006-12-28 Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese MA28689B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57665204P 2004-06-03 2004-06-03
US62653104P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
MA28689B1 true MA28689B1 (fr) 2007-06-01

Family

ID=34971944

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29573A MA28689B1 (fr) 2004-06-03 2006-12-28 Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese

Country Status (30)

Country Link
US (3) US7563791B2 (fr)
EP (1) EP1765823B1 (fr)
JP (1) JP4958772B2 (fr)
KR (1) KR101235602B1 (fr)
CN (1) CN1993361B (fr)
AR (1) AR049138A1 (fr)
AT (1) ATE462708T1 (fr)
AU (1) AU2005252217B2 (fr)
BR (1) BRPI0510848A (fr)
CA (1) CA2569396C (fr)
DE (1) DE602005020293D1 (fr)
EC (1) ECSP067043A (fr)
ES (1) ES2342722T3 (fr)
GT (1) GT200500137A (fr)
HN (1) HN2005000255A (fr)
IL (1) IL179264A0 (fr)
MA (1) MA28689B1 (fr)
MX (1) MX279139B (fr)
MY (1) MY145077A (fr)
NO (1) NO20070049L (fr)
NZ (1) NZ551742A (fr)
PE (1) PE20060243A1 (fr)
PH (1) PH12006502386B1 (fr)
RU (1) RU2401269C2 (fr)
SG (1) SG127661A1 (fr)
SV (1) SV2006002134A (fr)
TW (1) TW200608979A (fr)
UY (1) UY28931A1 (fr)
WO (1) WO2005121147A1 (fr)
ZA (1) ZA200700011B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP1957485B1 (fr) * 2005-12-02 2013-02-13 Bayer HealthCare, LLC Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MEP3808A (xx) 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
EP1882475A1 (fr) * 2006-07-26 2008-01-30 Novartis AG Méthodes de traitement de maladies médiées par le récepteur du facteur de croissance fibroblastique
US7912582B1 (en) * 2007-05-03 2011-03-22 Innovation Associates, Inc. Robotic prescription filling system
NZ583790A (en) * 2007-09-10 2012-04-27 Cipla Ltd Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
US8138336B2 (en) * 2007-09-25 2012-03-20 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
EP2085397A1 (fr) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Forme cristalline d'abacavir
AR074830A1 (es) 2008-12-19 2011-02-16 Cephalon Inc Pirrolotriazinas como inhibidores de alk y jak2
EP2739144A4 (fr) * 2011-06-20 2015-04-01 Alzheimer S Inst Of America Inc Composés et ses utilisations thérapeutiques
CN103764657B (zh) 2011-07-01 2016-05-25 拜耳知识产权有限责任公司 作为alk1抑制剂的羟甲基芳基取代的吡咯并三嗪
ES2570862T3 (es) 2011-12-15 2016-05-20 Bayer Ip Gmbh Benzotienil-pirrolotriazinas sustituidas y usos de las mismas en el tratamiento de cáncer
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
WO2013124316A1 (fr) 2012-02-23 2013-08-29 Bayer Intellectual Property Gmbh Pyrrolotriazines de benzothiényle substitués et leurs utilisations
TN2016000555A1 (en) * 2014-06-17 2018-04-04 Chiesi Farm Spa Indolizine derivatives as phosphoinositide 3-kinases inhibitors
WO2017035366A1 (fr) 2015-08-26 2017-03-02 Incyte Corporation Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam
US10221191B2 (en) 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10125123B2 (en) * 2016-03-03 2018-11-13 Cornell University Small molecule IRE1-α inhibitors
EP3436461B1 (fr) 2016-03-28 2023-11-01 Incyte Corporation Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
WO2018161033A1 (fr) * 2017-03-02 2018-09-07 Wright, Adrian Inhibiteurs ire1-alpha à petites molécules
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
MY208007A (en) 2017-09-27 2025-04-04 Incyte Corp Salts of pyrrolotriazine derivatives useful as tam inhibitors
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
EP3898609A1 (fr) 2018-12-19 2021-10-27 Shy Therapeutics LLC Composés interagissant avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladie fibrotique
MX2021007925A (es) 2018-12-31 2021-10-26 Biomea Fusion Llc Inhibidores irreversibles de la interaccion menina-mll.
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
MX2021013146A (es) * 2019-05-13 2022-01-24 Relay Therapeutics Inc Inhibidores de receptores del factor de crecimiento de fibroblastos (fgfr) y metodos de uso de los mismos.
BR112022005674A2 (pt) * 2019-09-26 2022-06-21 Shenzhen Targetrx Inc Derivado de anel fundido aromático substituído e composição compreendendo o mesmo, e uso do mesmo
EP4114401A1 (fr) 2020-03-06 2023-01-11 Incyte Corporation Polythérapie comprenant des inhibiteurs d'axl/mer et de pd-1/pd-l1
JP7556604B2 (ja) * 2020-07-10 2024-09-26 範恩柯爾生物科技（中山）有限公司 トリアジン系化合物およびその組成物と用途
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
CA3228627A1 (fr) 2021-08-11 2023-02-16 Thomas Butler Inhibiteurs covalents de l'interaction menine-mll pour le diabete sucre
CN119816500A (zh) 2021-08-20 2025-04-11 拜欧米富士恩公司 用于治疗癌症的不可逆menin-MLL抑制剂N-[4-[4-(4-吗啉基)-7H-吡咯并[2,3-d]嘧啶-6-基]苯基]-4-[[3(R)-[(1-氧代-2-丙烯-1-基)氨基]-1-哌啶基]甲基]-2-吡啶甲酰胺的结晶形式
WO2024155719A1 (fr) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Formes cristallines de n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phényl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-pipéridinyl]méthyl]-2- pyridinecarboxamide en tant qu'inhibiteur covalent de l'interaction ménine-mll

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2097384C1 (ru) * 1989-10-31 1997-11-27 Биокрист Фармасьютикалз Инк. Производные 2-амино-7-(chr2r3)-3н,5н-пирроло[3,2-d]-пиримидин-4-она, способы их получения и способ селективного ингибирования пролиферации т-лимфоцитов млекопитающего и не оказывающий воздействия на b-лимфоциты
KR100666514B1 (ko) * 1999-05-21 2007-02-28 브리스톨-마이어즈 스퀴브 컴페니 키나제의 피롤로트리아진 저해제
NZ525334A (en) * 2000-11-17 2005-07-29 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
AU2003265349A1 (en) * 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP1694686A1 (fr) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Inhibiteurs de kinase
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP1957485B1 (fr) * 2005-12-02 2013-02-13 Bayer HealthCare, LLC Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
US8138336B2 (en) * 2007-09-25 2012-03-20 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase

Also Published As

Publication number Publication date
UY28931A1 (es) 2005-12-30
DE602005020293D1 (de) 2010-05-12
NZ551742A (en) 2010-08-27
EP1765823A1 (fr) 2007-03-28
AU2005252217B2 (en) 2011-05-12
CA2569396A1 (fr) 2005-12-22
US20070208013A1 (en) 2007-09-06
JP2008501703A (ja) 2008-01-24
HN2005000255A (es) 2010-09-17
PH12006502386B1 (en) 2010-12-23
MX279139B (es) 2010-09-21
IL179264A0 (en) 2007-03-08
KR101235602B1 (ko) 2013-02-21
CA2569396C (fr) 2011-12-20
RU2401269C2 (ru) 2010-10-10
WO2005121147A1 (fr) 2005-12-22
CN1993361B (zh) 2010-05-26
SG127661A1 (en) 2007-01-30
NO20070049L (no) 2007-01-30
PE20060243A1 (es) 2006-04-21
RU2006147237A (ru) 2008-07-20
US20100075958A1 (en) 2010-03-25
JP4958772B2 (ja) 2012-06-20
EP1765823B1 (fr) 2010-03-31
ECSP067043A (es) 2006-12-29
MY145077A (en) 2011-12-15
AR049138A1 (es) 2006-06-28
ATE462708T1 (de) 2010-04-15
BRPI0510848A (pt) 2007-11-27
AU2005252217A1 (en) 2005-12-22
KR20070035028A (ko) 2007-03-29
GT200500137A (es) 2006-05-18
US20130225809A1 (en) 2013-08-29
US7563791B2 (en) 2009-07-21
CN1993361A (zh) 2007-07-04
SV2006002134A (es) 2006-10-04
US8338595B2 (en) 2012-12-25
ES2342722T3 (es) 2010-07-13
ZA200700011B (en) 2008-11-26
MXPA06013457A (es) 2007-03-01
TW200608979A (en) 2006-03-16
HK1109141A1 (en) 2008-05-30

Similar Documents

Publication Publication Date Title
MA28689B1 (fr) Derives de pyrrozolotriazine utiles pour le traitement des troubles et maladies hyperproliferatifs associes a l'angiogenese
EP1957077A4 (fr) Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
MA26992A1 (fr) Derives de phenethanolamine pour le traitement des maladies respiratoires
EP2096919A4 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
EP1357908A4 (fr) Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
EP1311261A4 (fr) Medicaments pour le traitement chimiotherapeutique de maladies
EP2120938A4 (fr) Analogues de l'imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires
EP1816913A4 (fr) Nouveaux composes utiles pour le traitement du cancer et des troubles associes a la fonction d'angiogenese
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
NO20032801D0 (no) Tiazolderivater for behandling av PPAR relaterte forstyrrelser
FR13C0029I1 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP1534074A4 (fr) Polytherapie pour le traitement de l'obesite
MA27027A1 (fr) Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
MA28871B1 (fr) Derives tricycliques accoles pour le traitement de troubles psychotiques
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
MA26951A1 (fr) Derives de pyrazole pour le traitement de maladies virales
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
NO20041833L (no) Heterocykliske forbindelser for anvendelse i behandlingen av forstyrrelser i urinveissystemet
MA28806B1 (fr) Derives d'arylsulfonylstilbene destines au traitement de l'insomnie et de conditions apparentees
MA26779A1 (fr) Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central.
MA29085B1 (fr) Agent prophylactique ou thérapeutique pour le traitement des troubles du sommeil
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease